<i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.

Coupez, Dahna; Hulo, Pauline; Touchefeu, Yann; Denis, Marc G; Bennouna, Jaafar

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.

Coupez, Dahna; Hulo, Pauline; Touchefeu, Yann; Denis, Marc G; Bennouna, Jaafar.

Afiliação

Coupez D; Medical Oncology Department, University Hospital of Nantes, France.
Hulo P; Medical Oncology Department, University Hospital of Nantes, France.
Touchefeu Y; Medical Oncology Department, University Hospital of Nantes, France.
Denis MG; Institut des Maladies de l'Appareil Digestif, University Hospital of Nantes, France.
Bennouna J; Department of Biochemistry, Centre Hospitalier Universitaire Nantes, Nantes, France.

Expert Opin Biol Ther ; 21(10): 1325-1334, 2021 10.

Article em En | MEDLINE | ID: mdl-34378483

Assuntos

Antineoplásicos/uso terapêutico; Neoplasias Colorretais; Proteínas Proto-Oncogênicas p21(ras); Biomarcadores Tumorais; Neoplasias Colorretais/tratamento farmacológico; Neoplasias Colorretais/genética; Humanos; Mutação; Medicina de Precisão; Proteínas Proto-Oncogênicas p21(ras)/genética

Palavras-chave

Colorectal cancer; KRAS inhibitors; RAS mutations; SHP2; SOS1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Expert Opin Biol Ther Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google